Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Correvio Pharma Corp. CORV

Healthcare Drug Manufacturers - Major
Correvio Pharma Corp is specialty pharmaceutical company. It offers patients and healthcare providers therapeutic solutions for acute medical conditions to improve health and quality of life. Its products are Aggrastat, Esmocard, Brinavess, Xydalba, Zevtera/Mabelio, and others. It offers solutions on Acute Bacterial Skin and Skin Structure Infections, Acute Coronary Syndromes, Atrial... see more

Recent & Breaking News (NDAQ:CORV)

Correvio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

PR Newswire September 4, 2019

Correvio Announces Presentation Of Brinavess® Spectrum Data At The European Society Of Cardiology 2019 Congress

Canada NewsWire September 3, 2019

Correvio Reports Second Quarter 2019 Financial Results

PR Newswire August 14, 2019

Correvio Announces Brinavess® Spectrum Data to be Presented at the European Society of Cardiology 2019 Congress

PR Newswire August 12, 2019

Correvio to Report Second Quarter 2019 Financial Results

Canada NewsWire August 8, 2019

Correvio Closes Public Offering of 9,200,000 Common Shares

Canada NewsWire August 7, 2019

Correvio Announces Pricing Of Public Offering Of Common Shares

Canada NewsWire August 2, 2019

Correvio Announces Overnight Marketed Offering of Common Shares

Canada NewsWire August 1, 2019

U.S. FDA Accepts Correvio's Resubmitted New Drug Application For Brinavess (vernakalant)

PR Newswire July 25, 2019

Correvio Resubmits Brinavess (Vernakalant) New Drug Application to U.S. FDA for the Treatment of Patients with Recent Onset Atrial Fibrillation

Canada NewsWire June 24, 2019

Correvio Announces Voting Results

Canada NewsWire June 18, 2019

Correvio Reports First Quarter 2019 Financial Results

Canada NewsWire May 8, 2019

Correvio to Report First Quarter 2019 Financial Results on May 8, 2019

Canada NewsWire May 1, 2019

Correvio Announces Zevtera® Abstracts at ECCMID 2019

Canada NewsWire April 3, 2019

Correvio Announces Xydalba™ (Dalbavancin Hydrochloride) Abstracts at ECCMID 2019

Canada NewsWire April 3, 2019

Correvio to present at the H.C. Wainwright Global Life Sciences Conference

Canada NewsWire April 2, 2019

Correvio Announces Presentation Of Brinavess® Data At The American College Of Cardiology 2019 Annual Meeting

Canada NewsWire March 20, 2019

Correvio Announces at the Market Offering

PR Newswire March 14, 2019

Correvio Reports Fourth Quarter and Full Year 2018 Financial Results

Canada NewsWire March 13, 2019

Correvio Announces Amendment To Term Loan With CRG-Managed Funds

Canada NewsWire March 11, 2019